Amyotrophic Lateral Sclerosis - Cell Based Therapy and Novel Therapeutic Development

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the loss of motor neurons, leading to premature death. Current treatments offer minimal delay in disease progression, prompting the search for novel therapies. Cell-based therapy, particularly stem cell transplantation, has emerged as a potential regenerative approach for ALS by replacing damaged motor neurons. The advent of induced pluripotent stem cell (iPSC) technology offers possibilities for patient-specific disease modeling and autologous cell transplantation, broadening therapeutic options for ALS.

• 1
  Mesenchymal stem cell (MSC) transplantation has shown minor improvements in ALS patients, with some studies suggesting that pre-selecting MSCs based on biomarkers could optimize treatment outcomes.
• 2
  Neural stem cell transplantation, particularly using human fetal spinal cord-derived neural stem cells (HSSC), has demonstrated potential for replacing dying motor neurons in ALS.
• 3
  Induced pluripotent stem cell (iPSC) technology enables the generation of patient-derived iPSCs for disease modeling and drug screening, offering personalized therapeutic approaches for ALS.